GSK, who was already a minority shareholder in GlycoVaxyn, acquires the company and its biological conjugation platform which may help it to develop a new generation of prophylactic vaccines against bacterial infections. GSK has today paid €167M to purchase the remaining stake in the company.
GlycoVaxyn’s innovative biological conjugation platform originates enables the development of a new generation of vaccines. The platform produces conjugate vaccines in bacterial cells by using biotechnology, avoiding chemical conjugation. It also allows the development of innovative vaccines for a wider range of indications which cannot be produced with a traditional chemical technology.
The company, a spin off from the Swiss Federal Institute of Technology (ETH Zurich), entered into research collaboration with GSK in 2012. The Swiss firm is in Phase I clinical trials with a vaccine candidate against Escherichia coli infections and is expected to initiate a Phase I for a vaccine against Shigellosis (severe diarrhea) in the US in the first quarter 2015 with the financial support of the Wellcome Trust.